Bachem Holding AG Overview
Pro stress-test →Bachem specializes in the development and manufacture of peptides and oligonucleotides, providing products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies. The company operates a critical CDMO (contract development and manufacturing organization) role in the biotech supply chain, serving a growing market demand for peptide-based therapeutics.
Strategic Profile
Pro stress-test →Bachem is building new capacity to manufacture peptides at ton-scale for medicines in urgent demand. The company aims for annual sales of more than CHF 1 billion and an EBITDA margin of over 30% in 2026. With strong organic growth and aggressive capacity expansion, Bachem is positioned as the leading peptide CDMO in a high-growth market segment.
Competitive Landscape
Pro stress-test →Lonza Group is identified as one of Bachem's main competitors. Bachem competes in the specialized CDMO market focused on peptides and oligonucleotides. The market is consolidating around specialized providers, where Bachem holds a leading position due to its peptide manufacturing scale and capabilities.
Industry Context
Bachem Holding AG operates in Pharmaceutical Contract Development and Manufacturing (CDMO) - Peptides & Oligonucleotides.
Key facts
Founded: 1971 · Headquarters: Bubendorf, Switzerland · Employees: 2,200 · Revenue: $781M · Market cap: $4.58B